<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515463</url>
  </required_header>
  <id_info>
    <org_study_id>20060237</org_study_id>
    <nct_id>NCT00515463</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density</brief_title>
  <official_title>A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the immunogenicity profiles of denosumab pre-filled
      syringe (PFS) and vial at 6 months in postmenopausal women with low bone mineral density
      (BMD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neutralizing Antibodies Against Denosumab at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Samples demonstrating reactivity for binding antibodies to denosumab were to be tested for neutralizing or inhibitory effects in a cell-based bioassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium Change From Baseline at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Sodium Change From Baseline at Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chloride Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chloride Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chloride Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bicarbonate Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bicarbonate Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bicarbonate Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry bicarbonate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnesium Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnesium Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnesium Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry magnesium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Nitrogen Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Nitrogen Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Nitrogen Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Amino Transferase Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry aspartate amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Amino Transferase Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry aspartate amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Amino Transferase Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry aspartate amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Amino Transferase Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry alanine amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Amino Transferase Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry alanine amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Amino Transferase Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry alanine amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry total bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Protein Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Protein Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Protein Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory chemistry glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory chemistry glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory chemistry glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cells Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cells Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cells Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology red blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocytes Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology reticulocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocytes Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology reticulocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocytes Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology reticulocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cells Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology white blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cells Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology white blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cells Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology white blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Neutrophils Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology total neutrophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Neutrophils Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology total neutrophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Neutrophils Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology total neutrophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophils Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophils Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophils Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basophils Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basophils Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basophils Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology basophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes Change From Baseline at Month 1</measure>
    <time_frame>Baseline, month 1</time_frame>
    <description>Laboratory hematology monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes Change From Baseline at Month 6</measure>
    <time_frame>Baseline, month 6</time_frame>
    <description>Laboratory hematology monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes Change From Baseline at Month 12</measure>
    <time_frame>Baseline, month 12</time_frame>
    <description>Laboratory hematology monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Toxicity CTCAE Grade Greater or Equal to 3</measure>
    <time_frame>Day 1 to Month 12</time_frame>
    <description>Participants with laboratory toxicity grade 3 (severe) or 4 (life-threatening), based on the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Low Bone Mineral Density</condition>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab - Vial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab - Prefilled syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denosumab</intervention_name>
    <description>60 mg denosumab in 1mL</description>
    <arm_group_label>Denosumab - Vial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denosumab</intervention_name>
    <description>60 mg denosumab in 1mL</description>
    <arm_group_label>Denosumab - Prefilled syringe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have successfully completed the 20050141 study (NCT00330460):

               -  Must have received all SC investigational product administrations in 20050141

               -  Must not have taken any proscribed therapies in 20050141

               -  Subjects who were in the alendronate or denosumab treatment group are allowed

          -  Provide signed informed consent before any study-specific procedures are conducted

        Exclusion Criteria:

          -  Any disorder that, in the opinion of the investigator, may compromise the ability of
             the patient to give written informed consent and/or comply with study procedures
             including:

               -  Any physical or psychiatric disorder

               -  Or evidence of alcohol or substance abuse in the last 12 months

          -  Any clinical evidence, in the medical judgement of the investigator, of the following
             medical conditions:

               -  Impaired thyroid function (subsequent to treatment)

               -  Impaired hepatic function

               -  Impaired renal function

               -  Rheumatoid Arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or
                  cirrhosis of the liver

               -  Known to have tested positive for human immunodeficiency virus, hepatitis C
                  virus, or hepatitis B surface antigen

               -  Any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, which
                  may interfere with the interpretation of the findings
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2007</study_first_submitted>
  <study_first_submitted_qc>August 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2007</study_first_posted>
  <results_first_submitted>June 18, 2010</results_first_submitted>
  <results_first_submitted_qc>August 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2013</results_first_posted>
  <disposition_first_submitted>November 23, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 23, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 25, 2009</disposition_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteopenia</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>AMG 162</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Pre-filled syringe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients who successfully completed Study 20050141 (NCT00330460) were eligible to participate in this study.
First Subject Enrolled: 30-May-2007 Last Subject Enrolled: 10-Sep-2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Denosumab - Vial</title>
          <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
        </group>
        <group group_id="P2">
          <title>Denosumab - Pre-filled Syringe</title>
          <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Denosumab - Vial</title>
          <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
        </group>
        <group group_id="B2">
          <title>Denosumab - Pre-filled Syringe</title>
          <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="311"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="8.5"/>
                    <measurement group_id="B2" value="62.9" spread="8.9"/>
                    <measurement group_id="B3" value="62.7" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6</title>
        <description>An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.</description>
        <time_frame>6 months</time_frame>
        <population>Patients who received ≥ 1 dose of investigational product, have a baseline and ≥ 1 post-baseline antibody assessment and did not have binding anti-denosumab antibodies present at baseline, and with evaluable antibody results at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe (PFS) on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6</title>
          <description>An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.</description>
          <population>Patients who received ≥ 1 dose of investigational product, have a baseline and ≥ 1 post-baseline antibody assessment and did not have binding anti-denosumab antibodies present at baseline, and with evaluable antibody results at 6 months.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Risk difference &gt; 0 indicates that incidence of binding anti-denosumab antibodies in denosumab PFS is greater than denosumab vial. 95% CI based on a normal approximation with continuity correction.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 12</title>
        <description>An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.</description>
        <time_frame>12 months</time_frame>
        <population>Patients who received ≥ 1 dose of investigational product, have a baseline and ≥ 1 post-baseline antibody assessment and did not have binding anti-denosumab antibodies present at baseline, and with evaluable antibody results at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 12</title>
          <description>An electrochemiluminescent bridging immunoassay was used to test blood samples for binding antibodies to denosumab.</description>
          <population>Patients who received ≥ 1 dose of investigational product, have a baseline and ≥ 1 post-baseline antibody assessment and did not have binding anti-denosumab antibodies present at baseline, and with evaluable antibody results at 12 months.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neutralizing Antibodies Against Denosumab at Month 12</title>
        <description>Samples demonstrating reactivity for binding antibodies to denosumab were to be tested for neutralizing or inhibitory effects in a cell-based bioassay.</description>
        <time_frame>Month 12</time_frame>
        <population>Patients testing positive for binding antibodies to denosumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutralizing Antibodies Against Denosumab at Month 12</title>
          <description>Samples demonstrating reactivity for binding antibodies to denosumab were to be tested for neutralizing or inhibitory effects in a cell-based bioassay.</description>
          <population>Patients testing positive for binding antibodies to denosumab.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sodium Change From Baseline at Month 1</title>
        <description>Laboratory chemistry sodium</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium Change From Baseline at Month 1</title>
          <description>Laboratory chemistry sodium</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.0"/>
                    <measurement group_id="O2" value="0.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sodium Change From Baseline at Month 6</title>
        <description>Laboratory chemistry sodium</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium Change From Baseline at Month 6</title>
          <description>Laboratory chemistry sodium</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.0"/>
                    <measurement group_id="O2" value="-0.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sodium Change From Baseline at Month 12</title>
        <description>Sodium Change From Baseline at Month 12</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium Change From Baseline at Month 12</title>
          <description>Sodium Change From Baseline at Month 12</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.1"/>
                    <measurement group_id="O2" value="-0.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potassium Change From Baseline at Month 1</title>
        <description>Laboratory chemistry potassium</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Potassium Change From Baseline at Month 1</title>
          <description>Laboratory chemistry potassium</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.37"/>
                    <measurement group_id="O2" value="0" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potassium Change From Baseline at Month 6</title>
        <description>Laboratory chemistry potassium</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Potassium Change From Baseline at Month 6</title>
          <description>Laboratory chemistry potassium</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.43"/>
                    <measurement group_id="O2" value="-0.07" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potassium Change From Baseline at Month 12</title>
        <description>Laboratory chemistry potassium</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Potassium Change From Baseline at Month 12</title>
          <description>Laboratory chemistry potassium</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.40"/>
                    <measurement group_id="O2" value="0.04" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chloride Change From Baseline at Month 1</title>
        <description>Laboratory chemistry chloride</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Chloride Change From Baseline at Month 1</title>
          <description>Laboratory chemistry chloride</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.1"/>
                    <measurement group_id="O2" value="0.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chloride Change From Baseline at Month 6</title>
        <description>Laboratory chemistry chloride</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Chloride Change From Baseline at Month 6</title>
          <description>Laboratory chemistry chloride</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.3"/>
                    <measurement group_id="O2" value="-0.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chloride Change From Baseline at Month 12</title>
        <description>Laboratory chemistry chloride</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Chloride Change From Baseline at Month 12</title>
          <description>Laboratory chemistry chloride</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.1"/>
                    <measurement group_id="O2" value="0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bicarbonate Change From Baseline at Month 1</title>
        <description>Laboratory chemistry bicarbonate</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Bicarbonate Change From Baseline at Month 1</title>
          <description>Laboratory chemistry bicarbonate</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.9"/>
                    <measurement group_id="O2" value="0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bicarbonate Change From Baseline at Month 6</title>
        <description>Laboratory chemistry bicarbonate</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Bicarbonate Change From Baseline at Month 6</title>
          <description>Laboratory chemistry bicarbonate</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.7"/>
                    <measurement group_id="O2" value="0.1" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bicarbonate Change From Baseline at Month 12</title>
        <description>Laboratory chemistry bicarbonate</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Bicarbonate Change From Baseline at Month 12</title>
          <description>Laboratory chemistry bicarbonate</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.8"/>
                    <measurement group_id="O2" value="-0.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnesium Change From Baseline at Month 1</title>
        <description>Laboratory chemistry magnesium</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnesium Change From Baseline at Month 1</title>
          <description>Laboratory chemistry magnesium</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.092"/>
                    <measurement group_id="O2" value="-0.010" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnesium Change From Baseline at Month 6</title>
        <description>Laboratory chemistry magnesium</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnesium Change From Baseline at Month 6</title>
          <description>Laboratory chemistry magnesium</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.053" spread="0.073"/>
                    <measurement group_id="O2" value="-0.064" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnesium Change From Baseline at Month 12</title>
        <description>Laboratory chemistry magnesium</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnesium Change From Baseline at Month 12</title>
          <description>Laboratory chemistry magnesium</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.053" spread="0.062"/>
                    <measurement group_id="O2" value="-0.055" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Urea Nitrogen Change From Baseline at Month 1</title>
        <description>Laboratory chemistry blood urea nitrogen</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Urea Nitrogen Change From Baseline at Month 1</title>
          <description>Laboratory chemistry blood urea nitrogen</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="1.30"/>
                    <measurement group_id="O2" value="-0.04" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Urea Nitrogen Change From Baseline at Month 6</title>
        <description>Laboratory chemistry blood urea nitrogen</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Urea Nitrogen Change From Baseline at Month 6</title>
          <description>Laboratory chemistry blood urea nitrogen</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="1.40"/>
                    <measurement group_id="O2" value="0.11" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Urea Nitrogen Change From Baseline at Month 12</title>
        <description>Laboratory chemistry blood urea nitrogen</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Urea Nitrogen Change From Baseline at Month 12</title>
          <description>Laboratory chemistry blood urea nitrogen</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="1.44"/>
                    <measurement group_id="O2" value="-0.02" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Change From Baseline at Month 1</title>
        <description>Laboratory chemistry creatinine</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Change From Baseline at Month 1</title>
          <description>Laboratory chemistry creatinine</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="8.01"/>
                    <measurement group_id="O2" value="0.12" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Change From Baseline at Month 6</title>
        <description>Laboratory chemistry creatinine</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Change From Baseline at Month 6</title>
          <description>Laboratory chemistry creatinine</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="8.52"/>
                    <measurement group_id="O2" value="-1.29" spread="8.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Change From Baseline at Month 12</title>
        <description>Laboratory chemistry creatinine</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Change From Baseline at Month 12</title>
          <description>Laboratory chemistry creatinine</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="9.53"/>
                    <measurement group_id="O2" value="0.76" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Amino Transferase Change From Baseline at Month 1</title>
        <description>Laboratory chemistry aspartate amino transferase</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Amino Transferase Change From Baseline at Month 1</title>
          <description>Laboratory chemistry aspartate amino transferase</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="13.0"/>
                    <measurement group_id="O2" value="0.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Amino Transferase Change From Baseline at Month 6</title>
        <description>Laboratory chemistry aspartate amino transferase</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Amino Transferase Change From Baseline at Month 6</title>
          <description>Laboratory chemistry aspartate amino transferase</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="13.9"/>
                    <measurement group_id="O2" value="0.9" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Amino Transferase Change From Baseline at Month 12</title>
        <description>Laboratory chemistry aspartate amino transferase</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Amino Transferase Change From Baseline at Month 12</title>
          <description>Laboratory chemistry aspartate amino transferase</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="13.5"/>
                    <measurement group_id="O2" value="0.2" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Amino Transferase Change From Baseline at Month 1</title>
        <description>Laboratory chemistry alanine amino transferase</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Amino Transferase Change From Baseline at Month 1</title>
          <description>Laboratory chemistry alanine amino transferase</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="25.7"/>
                    <measurement group_id="O2" value="0.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Amino Transferase Change From Baseline at Month 6</title>
        <description>Laboratory chemistry alanine amino transferase</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Amino Transferase Change From Baseline at Month 6</title>
          <description>Laboratory chemistry alanine amino transferase</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="27.8"/>
                    <measurement group_id="O2" value="4.2" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Amino Transferase Change From Baseline at Month 12</title>
        <description>Laboratory chemistry alanine amino transferase</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Amino Transferase Change From Baseline at Month 12</title>
          <description>Laboratory chemistry alanine amino transferase</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="28.8"/>
                    <measurement group_id="O2" value="1.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Bilirubin Change From Baseline at Month 1</title>
        <description>Laboratory chemistry total bilirubin</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin Change From Baseline at Month 1</title>
          <description>Laboratory chemistry total bilirubin</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="2.53"/>
                    <measurement group_id="O2" value="-0.02" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Bilirubin Change From Baseline at Month 6</title>
        <description>Laboratory chemistry total bilirubin</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin Change From Baseline at Month 6</title>
          <description>Laboratory chemistry total bilirubin</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="2.54"/>
                    <measurement group_id="O2" value="-0.20" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Bilirubin Change From Baseline at Month 12</title>
        <description>Laboratory chemistry total bilirubin</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin Change From Baseline at Month 12</title>
          <description>Laboratory chemistry total bilirubin</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="2.68"/>
                    <measurement group_id="O2" value="0.64" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albumin Change From Baseline at Month 1</title>
        <description>Laboratory chemistry albumin</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin Change From Baseline at Month 1</title>
          <description>Laboratory chemistry albumin</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="1.68"/>
                    <measurement group_id="O2" value="-0.40" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albumin Change From Baseline at Month 6</title>
        <description>Laboratory chemistry albumin</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin Change From Baseline at Month 6</title>
          <description>Laboratory chemistry albumin</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="1.92"/>
                    <measurement group_id="O2" value="-0.51" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albumin Change From Baseline at Month 12</title>
        <description>Laboratory chemistry albumin</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin Change From Baseline at Month 12</title>
          <description>Laboratory chemistry albumin</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="1.82"/>
                    <measurement group_id="O2" value="0" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Protein Change From Baseline at Month 1</title>
        <description>Laboratory chemistry total protein</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Protein Change From Baseline at Month 1</title>
          <description>Laboratory chemistry total protein</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="2.67"/>
                    <measurement group_id="O2" value="-0.54" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Protein Change From Baseline at Month 6</title>
        <description>Laboratory chemistry total protein</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Protein Change From Baseline at Month 6</title>
          <description>Laboratory chemistry total protein</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="3.00"/>
                    <measurement group_id="O2" value="-0.80" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Protein Change From Baseline at Month 12</title>
        <description>Laboratory chemistry total protein</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Protein Change From Baseline at Month 12</title>
          <description>Laboratory chemistry total protein</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="2.84"/>
                    <measurement group_id="O2" value="-0.91" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Change From Baseline at Month 1</title>
        <description>Laboratory chemistry glucose</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Change From Baseline at Month 1</title>
          <description>Laboratory chemistry glucose</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="1.27"/>
                    <measurement group_id="O2" value="0.03" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Change From Baseline at Month 6</title>
        <description>Laboratory chemistry glucose</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Change From Baseline at Month 6</title>
          <description>Laboratory chemistry glucose</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="1.37"/>
                    <measurement group_id="O2" value="0.05" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Change From Baseline at Month 12</title>
        <description>Laboratory chemistry glucose</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Change From Baseline at Month 12</title>
          <description>Laboratory chemistry glucose</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="1.27"/>
                    <measurement group_id="O2" value="0.08" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cells Change From Baseline at Month 1</title>
        <description>Laboratory hematology red blood cells</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cells Change From Baseline at Month 1</title>
          <description>Laboratory hematology red blood cells</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>10^12/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.21"/>
                    <measurement group_id="O2" value="0.02" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cells Change From Baseline at Month 6</title>
        <description>Laboratory hematology red blood cells</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cells Change From Baseline at Month 6</title>
          <description>Laboratory hematology red blood cells</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>10^12/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.22"/>
                    <measurement group_id="O2" value="0.04" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cells Change From Baseline at Month 12</title>
        <description>Laboratory hematology red blood cells</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cells Change From Baseline at Month 12</title>
          <description>Laboratory hematology red blood cells</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>10^12/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.22"/>
                    <measurement group_id="O2" value="0.02" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Change From Baseline at Month 1</title>
        <description>Laboratory hematology hemoglobin</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Change From Baseline at Month 1</title>
          <description>Laboratory hematology hemoglobin</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="6.00"/>
                    <measurement group_id="O2" value="-0.42" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Change From Baseline at Month 6</title>
        <description>Laboratory hematology hemoglobin</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Change From Baseline at Month 6</title>
          <description>Laboratory hematology hemoglobin</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="5.83"/>
                    <measurement group_id="O2" value="0.96" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Change From Baseline at Month 12</title>
        <description>Laboratory hematology hemoglobin</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Change From Baseline at Month 12</title>
          <description>Laboratory hematology hemoglobin</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="6.09"/>
                    <measurement group_id="O2" value="-0.22" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reticulocytes Change From Baseline at Month 1</title>
        <description>Laboratory hematology reticulocytes</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Reticulocytes Change From Baseline at Month 1</title>
          <description>Laboratory hematology reticulocytes</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="17.68"/>
                    <measurement group_id="O2" value="1.69" spread="17.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reticulocytes Change From Baseline at Month 6</title>
        <description>Laboratory hematology reticulocytes</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Reticulocytes Change From Baseline at Month 6</title>
          <description>Laboratory hematology reticulocytes</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.54" spread="19.22"/>
                    <measurement group_id="O2" value="15.21" spread="20.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reticulocytes Change From Baseline at Month 12</title>
        <description>Laboratory hematology reticulocytes</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Reticulocytes Change From Baseline at Month 12</title>
          <description>Laboratory hematology reticulocytes</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.09" spread="19.82"/>
                    <measurement group_id="O2" value="15.08" spread="19.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelets Change From Baseline at Month 1</title>
        <description>Laboratory hematology platelets</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelets Change From Baseline at Month 1</title>
          <description>Laboratory hematology platelets</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="33.20"/>
                    <measurement group_id="O2" value="2.48" spread="36.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelets Change From Baseline at Month 6</title>
        <description>Laboratory hematology platelets</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelets Change From Baseline at Month 6</title>
          <description>Laboratory hematology platelets</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.26" spread="32.16"/>
                    <measurement group_id="O2" value="21.49" spread="53.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelets Change From Baseline at Month 12</title>
        <description>Laboratory hematology platelets</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelets Change From Baseline at Month 12</title>
          <description>Laboratory hematology platelets</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.19" spread="42.07"/>
                    <measurement group_id="O2" value="15.60" spread="41.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>White Blood Cells Change From Baseline at Month 1</title>
        <description>Laboratory hematology white blood cells</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>White Blood Cells Change From Baseline at Month 1</title>
          <description>Laboratory hematology white blood cells</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="1.07"/>
                    <measurement group_id="O2" value="0.01" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>White Blood Cells Change From Baseline at Month 6</title>
        <description>Laboratory hematology white blood cells</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>White Blood Cells Change From Baseline at Month 6</title>
          <description>Laboratory hematology white blood cells</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="1.38"/>
                    <measurement group_id="O2" value="-0.08" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>White Blood Cells Change From Baseline at Month 12</title>
        <description>Laboratory hematology white blood cells</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>White Blood Cells Change From Baseline at Month 12</title>
          <description>Laboratory hematology white blood cells</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="1.38"/>
                    <measurement group_id="O2" value="0.24" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Neutrophils Change From Baseline at Month 1</title>
        <description>Laboratory hematology total neutrophils</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Neutrophils Change From Baseline at Month 1</title>
          <description>Laboratory hematology total neutrophils</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.85"/>
                    <measurement group_id="O2" value="-0.03" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Neutrophils Change From Baseline at Month 6</title>
        <description>Laboratory hematology total neutrophils</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Neutrophils Change From Baseline at Month 6</title>
          <description>Laboratory hematology total neutrophils</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="1.23"/>
                    <measurement group_id="O2" value="-0.02" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Neutrophils Change From Baseline at Month 12</title>
        <description>Laboratory hematology total neutrophils</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Neutrophils Change From Baseline at Month 12</title>
          <description>Laboratory hematology total neutrophils</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="1.15"/>
                    <measurement group_id="O2" value="0.12" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophils Change From Baseline at Month 1</title>
        <description>Laboratory hematology eosinophils</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophils Change From Baseline at Month 1</title>
          <description>Laboratory hematology eosinophils</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.065"/>
                    <measurement group_id="O2" value="-0.010" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophils Change From Baseline at Month 6</title>
        <description>Laboratory hematology eosinophils</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophils Change From Baseline at Month 6</title>
          <description>Laboratory hematology eosinophils</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.075"/>
                    <measurement group_id="O2" value="0.013" spread="0.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophils Change From Baseline at Month 12</title>
        <description>Laboratory hematology eosinophils</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophils Change From Baseline at Month 12</title>
          <description>Laboratory hematology eosinophils</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.071"/>
                    <measurement group_id="O2" value="0.025" spread="0.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basophils Change From Baseline at Month 1</title>
        <description>Laboratory hematology basophils</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Basophils Change From Baseline at Month 1</title>
          <description>Laboratory hematology basophils</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.025"/>
                    <measurement group_id="O2" value="0" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basophils Change From Baseline at Month 6</title>
        <description>Laboratory hematology basophils</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Basophils Change From Baseline at Month 6</title>
          <description>Laboratory hematology basophils</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.026"/>
                    <measurement group_id="O2" value="0.012" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basophils Change From Baseline at Month 12</title>
        <description>Laboratory hematology basophils</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Basophils Change From Baseline at Month 12</title>
          <description>Laboratory hematology basophils</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.026"/>
                    <measurement group_id="O2" value="0.006" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocytes Change From Baseline at Month 1</title>
        <description>Laboratory hematology lymphocytes</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocytes Change From Baseline at Month 1</title>
          <description>Laboratory hematology lymphocytes</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.43"/>
                    <measurement group_id="O2" value="0.04" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocytes Change From Baseline at Month 6</title>
        <description>Laboratory hematology lymphocytes</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocytes Change From Baseline at Month 6</title>
          <description>Laboratory hematology lymphocytes</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.37"/>
                    <measurement group_id="O2" value="-0.06" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocytes Change From Baseline at Month 12</title>
        <description>Laboratory hematology lymphocytes</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocytes Change From Baseline at Month 12</title>
          <description>Laboratory hematology lymphocytes</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.41"/>
                    <measurement group_id="O2" value="0.06" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocytes Change From Baseline at Month 1</title>
        <description>Laboratory hematology monocytes</description>
        <time_frame>Baseline, month 1</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Monocytes Change From Baseline at Month 1</title>
          <description>Laboratory hematology monocytes</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 1.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.12"/>
                    <measurement group_id="O2" value="0.01" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocytes Change From Baseline at Month 6</title>
        <description>Laboratory hematology monocytes</description>
        <time_frame>Baseline, month 6</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Monocytes Change From Baseline at Month 6</title>
          <description>Laboratory hematology monocytes</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 6.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.14"/>
                    <measurement group_id="O2" value="-0.03" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocytes Change From Baseline at Month 12</title>
        <description>Laboratory hematology monocytes</description>
        <time_frame>Baseline, month 12</time_frame>
        <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Monocytes Change From Baseline at Month 12</title>
          <description>Laboratory hematology monocytes</description>
          <population>Subjects who received ≥ 1 dose of investigational product with non-missing baseline and non-missing month 12.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.13"/>
                    <measurement group_id="O2" value="0.03" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Toxicity CTCAE Grade Greater or Equal to 3</title>
        <description>Participants with laboratory toxicity grade 3 (severe) or 4 (life-threatening), based on the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</description>
        <time_frame>Day 1 to Month 12</time_frame>
        <population>Patients who received ≥ 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab - Vial</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab - Pre-filled Syringe</title>
            <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Toxicity CTCAE Grade Greater or Equal to 3</title>
          <description>Participants with laboratory toxicity grade 3 (severe) or 4 (life-threatening), based on the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.</description>
          <population>Patients who received ≥ 1 dose of investigational product.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with CTCAE grade 3 or 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium – Grade 3 below normal (&lt; 130 – 120 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium – Grade 3 above normal (&gt;6.0–7.0 mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium –Grade 3 above normal (&gt;1.23–3.30mmol/L)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Denosumab - Vial</title>
          <description>Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.</description>
        </group>
        <group group_id="E2">
          <title>Denosumab - Pre-filled Syringe</title>
          <description>Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator’s discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

